Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 9/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011257 | 0.85 | CDA (0.52) | CDACDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15010376 | 0.84 | CDA (0.54) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15010708 | 0.82 | CDA (0.52) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15010372 | 0.78 | CDA (0.53) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15010369 | 0.78 | CDA (0.53) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15011370 | 0.76 | CDA (0.55) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15011368 | 0.76 | CDA (0.55) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15010642 | 0.75 | CDA (0.53) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15010641 | 0.75 | CDA (0.53) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL28871114 | 0.75 | CDA (0.53) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108157-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108157-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | STING1, MITF, RARA | CDA 67/4885CDK1 4790/4885SLC28A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.